Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Meprobamate (Andaxin) - Uses, Dose, MOA, Brands, Side effects

Meprobamate (Andaxin) is a non-benzodiazepine tranquilizer that is used in the short-term treatment of anxiety disorders.

Meprobamate Uses:

Anxiety:
- For helping with worries and nervousness:
- It's not the top choice, says groups like the American Psychiatric Association, World Federation of Societies of Biological Psychiatry, and British Association for Psychopharmacology, to use meprobamate first when treating anxiety problems.

Meprobamate (Andaxin) Dose in Adults:

Meprobamate (Andaxin) Dose in the treatment of Anxiety:

Take it by mouth: 1.2 to 1.6 grams per day, split into different times;
The most you should take in a day is 2.4 grams.

Discontinuation:

If you've been using it for a long time, you should gradually reduce the dose over two weeks before stopping.
This helps avoid withdrawal symptoms such as loss of appetite, difficulty sleeping, and feeling anxious.

Meprobamate (Andaxin) Dose in Childrens:

Meprobamate (Andaxin) Dose in the treatment of Anxiety:

Children ≥6 years:
- Take between 200 to 600 milligrams per day by mouth, spread across 2 to 3 doses.
- When stopping after using for a long time, make sure to gradually decrease the dose over two weeks.
- This is important to prevent withdrawal symptoms such as loss of appetite, trouble sleeping, and anxiety.
Adolescents:
- The dosage is the same as for adults.

Pregnancy Risk Category: D/ X

Not safe to use during pregnancy:
Avoid it because it can pass through the placenta, potentially leading to birth defects.

Use during breastfeeding

Present in breast milk:
It can be found in breast milk.

Dose in Kidney Disease:

The manufacturer doesn't suggest changing the dose, but you can follow these guidelines:
For kidney function between 10 to 50 mL/minute: Take it every 9 to 12 hours.
For kidney function less than 10 mL/minute: Take it every 12 to 18 hours.
For hemodialysis: No need to adjust the dosage.
For peritoneal dialysis: Take it every 12 to 18 hours.
For continuous renal replacement therapy (CRRT): Take it every 9 to 12 hours.

Dose in Liver disease:

No need to change the dose.

Side effects of Meprobamate (Andaxin):

Cardiovascular:
- Abnormal electroencephalogram
- Tachycardia
- Cardiac arrhythmia
- Peripheral edema
- Palpitations
- Severe hypotension
- Syncope
Central nervous system:
- Slurred speech
- Chills
- Paradoxical excitation
- Drowsiness Euphoria
- Overstimulation
- Headache
- Paresthesia
- Dizziness
- Vertigo
- Ataxia
Dermatologic:
- Dermatitis Erythema multiforme
- Skin rash
- Stevens-Johnson syndrome
Endocrine & metabolic:
- Exacerbation of porphyria
Gastrointestinal:
- Diarrhea
- Nausea
- Proctitis
- Stomatitis
- Vomiting
Genitourinary:
- Anuria
- Oliguria
Hematologic & oncologic:
- Bruise
- Agranulocytosis
- Purpura
- Aplastic anemia
- Leukopenia
- Immune thrombocytopenia
- Petechia
- Eosinophilia
Hypersensitivity:
- Angioedema
- Anaphylaxis
- Hypersensitivity reaction
Neuromuscular & skeletal:
- Weakness
Ophthalmic:
- Accommodation disturbance
Respiratory:
- Bronchospasm
Miscellaneous:
- Fever

Contraindications to Meprobamate (Andaxin):

If you're allergic or sensitive to meprobamate or any part of the medication, it's not suitable for you.

Warnings and precautions

Allergy reactions:
- If you already have skin problems, taking this medication might lead to allergic reactions, especially if you take the fourth dose.
Depression in the CNS:
- Be careful when using this product as it may cause CNS depression or drowsiness.
- If you use it along with alcohol or other sedatives, the risk of CNS depression increases.
Depression:
- It's important to handle patients with depression or thoughts of self-harm with extra care and attention.
Use of drugs:
- People who have a history of using or being dependent on drugs may be at risk of developing addiction.
- This could result in psychological tolerance.
Hepatic impairment:
- If someone already has liver problems, it's important to handle their condition with care.
Renal impairment:
- It's important to take pre-existing kidney problems into consideration.
Seizure disorder:
- If you have a seizure disorder, it's important to take preventive measures to avoid seizures.

Meprobamate: Drug Interaction

Risk Factor C (Monitor therapy)
Alcohol (Ethyl	CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).
Alizapride	May enhance the CNS depressant effect of CNS Depressants.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
Esketamine	May enhance the CNS depressant effect of CNS Depressants.
HydrOXYzine	May enhance the CNS depressant effect of CNS Depressants.
Kava Kava	May enhance the adverse/toxic effect of CNS Depressants.
Lofexidine	May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Magnesium Sulfate	May enhance the CNS depressant effect of CNS Depressants.
MetyroSINE	CNS Depressants may enhance the sedative effect of MetyroSINE.
Minocycline (Systemic)	May enhance the CNS depressant effect of CNS Depressants.
Nabilone	May enhance the CNS depressant effect of CNS Depressants.
Piribedil	CNS Depressants may enhance the CNS depressant effect of Piribedil.
Pramipexole	CNS Depressants may enhance the sedative effect of Pramipexole.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Yohimbine	May diminish the therapeutic effect of Antianxiety Agents.
Risk Factor D (Consider therapy modification)
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin. Risk
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk
Droperidol	May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Risk
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk
Lemborexant	May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Risk
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Risk
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Risk
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk
Risk Factor X (Avoid combination)
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.

Monitoring parameters:

Symptoms of anxiety:
Feeling worried or fearful
Restlessness
Rapid heartbeat
Sweating
Trouble concentrating
Muscle tension
Mental status:
Refers to a person's overall mental and emotional condition
Signs of overdose:
Confusion
Extreme drowsiness
Slurred speech
Unsteady movements
Seizures
Difficulty breathing
Loss of consciousness

How to administer?

You can take it after eating.

Mechanism of action of Meprobamate (Andaxin):

It reduces complex spinal reflexes that involve multiple neurons and affects the thalamus and limbic system.

Onset of action:

Sedation begins after about 1 hour

Metabolism:

Takes place in the liver

Elimination half-life:

Approximately 10 hours

Excretion:

8% to 20% is eliminated unchanged in urine
10% is excreted in feces as metabolites

International Brand Names of Meprobamate:

Andaxin
Centryl
Ecuanil
Equanil
Koligin
Meprate
Mepro
Meprobamat
Meprodil
Miltaun
Oasil
Pertranquil
Praol
Probamato
Probamyl
Procalmadiol
Quaname
Quanil
Reposo-Mono
Restenil
Sanobamat
Tranquilin
Visano

Meprobamate Brand Names in Pakistan:

No Brands Available in Pakistan.

Disclaimer Notice:

Emedz.net is not an online pharmacy:

We are not affiliated with any pharmaceutical companies:

Meprobamate (Andaxin) - Uses, Dose, MOA, Brands, Side effects

Meprobamate Uses:

Anxiety:

Meprobamate (Andaxin) Dose in Adults:

Meprobamate (Andaxin) Dose in the treatment of Anxiety:

Discontinuation:

Meprobamate (Andaxin) Dose in Childrens:

Meprobamate (Andaxin) Dose in the treatment of Anxiety:

Children ≥6 years:

Adolescents:

Pregnancy Risk Category: D/ X

Dose in Kidney Disease:

Dose in Liver disease:

Side effects of Meprobamate (Andaxin):

Cardiovascular:

Central nervous system:

Dermatologic:

Endocrine & metabolic:

Gastrointestinal:

Genitourinary:

Hematologic & oncologic:

Hypersensitivity:

Neuromuscular & skeletal:

Ophthalmic:

Respiratory:

Miscellaneous:

Contraindications to Meprobamate (Andaxin):

Warnings and precautions

Allergy reactions:

Depression in the CNS:

Depression:

Use of drugs:

Hepatic impairment:

Renal impairment:

Seizure disorder:

Monitoring parameters:

How to administer?

Mechanism of action of Meprobamate (Andaxin):

International Brand Names of Meprobamate:

Meprobamate Brand Names in Pakistan:

Recent Posts

Related Posts